RH324 for Advanced Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called RH324 for individuals with advanced non-small cell lung cancer. The goal is to determine the optimal dose by administering varying amounts of the drug. It targets those who have not found success with standard treatments such as chemotherapy, targeted therapy, and immunotherapy. Participants must have a measurable lung tumor and be capable of performing daily activities independently. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but it mentions a washout period (time without taking certain medications) for prior treatments. It's best to discuss your specific medications with the trial team.
Is there any evidence suggesting that RH324 is likely to be safe for humans?
Research has shown that RH324 underwent safety testing in people with advanced non-small cell lung cancer. The study explored different doses to assess tolerance. Results indicated that participants managed the treatment without severe side effects at the doses tested. This suggests RH324 is generally safe for humans, but it's important to remember that this is still early research. The safety information is limited to the participants in that study, so consulting a healthcare provider before joining a trial is always advisable.12345
Why do researchers think this study treatment might be promising?
RH324 is unique because it targets advanced lung cancer in a novel way, potentially offering benefits over traditional treatments like chemotherapy and targeted therapies that often focus on broad cancer cell elimination or specific genetic mutations. RH324's innovative mechanism of action might provide a more precise attack on cancer cells, minimizing damage to healthy cells. Researchers are excited about this treatment because it could lead to fewer side effects and improved effectiveness, offering new hope for patients with advanced lung cancer who have limited options.
What evidence suggests that RH324 might be an effective treatment for advanced lung cancer?
Research shows that RH324 is undergoing testing for advanced non-small cell lung cancer (NSCLC). This treatment targets specific proteins on cancer cells, potentially slowing or stopping cancer growth. Early studies have identified safe dosage levels for RH324, and this trial will explore various doses to find the most effective and safe option. Although detailed efficacy data remains limited, the emphasis on targeted therapy is promising, as similar treatments have proven beneficial in other NSCLC cases. Thus, RH324 could potentially manage the disease by disrupting cancer growth signals.23678
Are You a Good Fit for This Trial?
Adults over 18 with advanced non-small cell lung cancer who have tried all standard treatments without success. They must not be pregnant, agree to birth control, and abstain from alcohol and supplements. Participants need a life expectancy of more than 2 months, adequate organ function, no serious medical conditions or infections, and the ability to swallow capsules.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive oral RH324 in a dose-ranging study to assess safety and tolerability
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- RH324
Find a Clinic Near You
Who Is Running the Clinical Trial?
ReHeva Biosciences,Inc.
Lead Sponsor